3
A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.

Platinum-based anticancer drugs — cisplatin, oxaliplatin, and carboplatin — are used for chemotherapy in about half of cancer cases. They penetrate cells and interact with DNA molecules. The process is fatal for rapidly dividing cancer cells because the drugs prevent the duplication of DNA molecules, which is necessary for successful division. Since cancer cells divide rapidly, they are the first to be affected. Still, platinum derivatives have certain disadvantages: low stability under physiological conditions and high toxicity.

To create new drugs, a strategy that involves the development of hybrid molecules is often used in modern chemistry. Such substances consist of two or more active fragments that are linked by a linker into one molecule. They usually have a double action, characteristic of each of the fragments.

A chemist from RUDN University, candidate of biological sciences Kirill Kirsanov, created a series of new drugs: hybrids of cisplatin, lonidamine, and bexarotene. Lonidamine itself has an anti-tumour effect due to its ability to suppress energy metabolism in cancer cells. In combination with radiation therapy, it is used to treat brain tumours. Bexarotene is used for the treatment of lung cancer and breast cancer, as it inhibits the growth of tumour cells of hematopoietic and squamous origin.

A derivative of cisplatin with bexarotene turned out to be the most promising. A combination of succinic acid and ethylenediamine was used as a linker. In tests conducted on four tumour cell lines, the hybrid drug was 80 times more active than bexaroten and 20 times higher on average than cisplatin, and the new drug was 80 times more active than cisplatin on MCF7D cell line. Based on the resulting leading compound, new and more effective anti-tumour medications can be developed.

The paper was published in the journal Inorganica Chimica Acta

Visiting Professors View all
12 Dec 2024
In 2024, RUDN started accepting applications for the new annual Prize for Scientific Achievement in Chemistry. The award was established to honour contributions to fundamental and applied research, as well as merit in achieving the UN Sustainable Development Goals.
430
International Projects View all
Similar newsletter View all
08 Aug
Focusing on science as a way of life, sustainable development goals as a scientist's mission and new technological developments: RUDN honored leaders in science and innovation

The RUDN University Science and Innovation Prize winners were honoured at the extended meeting of the Academic Council. In 2024 the terms of the traditional RUDN University Prize were changed: for the first time the competition was announced in two categories: leading scientists and young scientists.

21
08 Aug
RUDN University scientist: Africa relies on small modular reactors to solve energy problems

According to the International Energy Agency (IEA), electricity consumption in Africa has increased by more than 100% over the past two years (2020-2022). However, 74.9% of this energy is still produced by burning organic fuels — natural gas, coal and oil. At the same time, the level of electrification on the continent remains extremely low — only 24%, while in other developing countries it reaches 40%. Even in grid-connected areas, electricity supply is often unreliable: industrial enterprises lose energy on an average of 56 days a year.

13
08 Aug
RUDN dentists developed a program that will accelerate the work of an orthodontist by 40%

Today, diagnosis and treatment planning with orthodontists takes several days. Also, complications can arise during treatment that slow down the patient's recovery process. For example, improper orthodontic treatment planning can lead to temporomandibular joint dysfunction.

23
Similar newsletter View all